Infliximab therapy in pediatric Takayasu's arteritis: report of two cases.
Takayasu arteritis (TA) is a chronic vasculitis of unknown etiology. Experience with anti-tumor necrosis factor alpha (anti-TNF) agents in difficult-to-treat patients with TA is limited and refers to adult patients. Here, we present two cases of pediatric TA treated with infliximab, in which clinical remission was observed. Anti-TNF treatment represents a useful therapy in pediatric Takayasu arteritis too, especially to avoid the risk of long-term corticosteroids toxicity.
Buonuomo
Paola Sabrina
PS
Division of Rheumatology, Department of Pediatrics, Ospedale Pediatrico Bambino Gesù, IRCCS, Piazza S. Onofrio, 4, 00135 Rome, Italy. psabrina.buonuomo@opbg.net
Bracaglia
Claudia
C
Campana
Andrea
A
Insalaco
Antonella
A
Pardeo
Manuela
M
Cortis
Elisabetta
E
Ugazio
Alberto G
AG
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D013625:Takayasu Arteritis / Q000628:therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab